Ceva Rapid Growth Expected to Continue in 2013

February 12, 2013 — Lenexa, Kan. — Ceva Holdings, Inc. today affirmed its continued growth in 2013for the North America market following the financial reporting results of its parent company, CevaSanté Animale. The company completed its consolidation of its North America headquarters operationsto the Lenexa campus in late fall, 2012. The move expanded the company workforce and has alreadyresulted in better synergies to serve customers more efficiently for both its Ceva Animal Health andCeva Biomune subsidiaries.

In 2012, Vectra® parasiticide sales grew 34.5 percent in the US. Feliway® and Adaptil® continued to driveexpansion of the behavior segment growing 30.4 percent. The company also entered the equine marketin the United States with the launch of Altresyn®(altrenogest).

In the avian market, Ceva captured the number two market position in 2012 after the successfulconclusion of Ceva’s integration of Vetech Laboratories, a Canadian poultry vaccine manufacturer thatmarkets live vaccines against coccidiosis. This allowed Ceva to add Vetech’s live coccidiosis vaccineImmucox T to the portfolio in the highly competitive United States market, expanding the poultryvaccine range from respiratory to also include intestinal health.

“We are coming off a very strong year and believe Ceva will continue growth with an outstanding teamin place, with great existing and new products, and with continued financial support and commitment tothe veterinary profession, “said Craig Wallace, Chief Executive Officer of Ceva Holdings, Inc.

Demonstrating Ceva’s commitment to grow its management team, Dr. Karen Padgett joined CevaJanuary 1 as Chief Operating Officer of the Ceva Animal Health Companion Animal Group. Padgett is a28-year veteran of the animal health industry, most of which has been spent at Hill’s Pet Nutrition, adivision of Colgate-Palmolive.

Upon being named to the position, Dr. Padgett said, “Ceva is a global company that is rapidly growing,but shows true commitment to the veterinary profession. I am thrilled to join the organization to leada dynamic team and continue to contribute to the veterinary profession in a meaningful way. It’s atremendous opportunity.”

The company plans to not only continue to market its products aggressively, but help educate petowners to drive traffic to veterinary clinics. The Vectra® brand will be supported in 2013 by a multi-media advertising campaign which includes TV advertising and a “first dose free” coupon program.

The Feliway® line will be extended with the introduction of new Feliway Wipes at the WesternVeterinary Conference. Both Adaptil® and Feliway® will be supported by a major nationwide BehaviorAdvocate Program and veterinary exclusive trial generating consumer programs. In addition, thesuccessful Keep The L.O.V.E. Alive public relations bus tour will be expanded. The tour is aimed atincreasing awareness that there are solutions to help keep pets from being put down due to unwantedbehavior issues.

Ceva Animal Health has increased its visibility in the veterinary profession by joining in the celebrationof the American Veterinary Medical Association’s 150th Anniversary as a sponsor. The company is alsoa sponsor of the One Health, One World initiative, is an inaugural sponsor of the American Associationof Feline Practitioner’s Cat Practice initiative, and continues its commitment to educating veterinariansthrough conference CE and a new state veterinary medical association program.

Ceva Biomune’s $7 million renovation to its R&D facility in Lenexa announced in July 2012 is expectedto be completed in June, 2013. The renovation will give the team 18,000 square feet of BSL-2 (bio safetylevel 2) laboratory space and 15,000 square feet of office space. In May 2011, Ceva completed an $18million expansion of its Biomune poultry vaccine production plant on the Ceva Biomune campus.

“Continued expansion of our research and manufacturing facilities is critical to meeting the needs of ourdomestic and global customers. We are on schedule to deliver on that investment and look forward tothe opening of the renovated R&D facility,” said Daryl Pint, Chief Executive Officer of Ceva Biomune.

Craig Wallace
CEO of Ceva Holdings, Inc.

Daryl Pint
CEO of Ceva Biomune

Dr. Karen Padgett
COO of Ceva Animal Health
Companion Animal Group

About Ceva Animal Health & Ceva Biomune: Ceva Animal Health’s key companion animal productsinclude the Vectra® line of parasiticides, Adaptil® and Feliway® pheromone behavior aids and Senilife®neuroprotection for aging pets. Ceva Biomune’s key poultry products include CEVAC® Transmune IBD,Vectormune® FP and Vectormune® HVT. The Ceva Biomune Campus and the Ceva North America Zoneheadquarters are both located in Lenexa, Kansas. Visit www.ceva.us.

About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused onthe research, development, production and marketing of pharmaceutical products and vaccines for pets,livestock, swine and poultry. Its headquarters is in Libourne, France. Visit www.ceva.com.


Comments are closed.